2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04390386 (ClinicalTrials.gov) | January 1, 2021 | 13/5/2020 | Controlled Study of IC14 for Treatment of ALS | Amyotrophic Lateral Sclerosis Trial: A Randomized, Double-Blind, Placebo-Controlled Study: IC14, a Monoclonal Antibody Against CD14 | Amyotrophic Lateral Sclerosis | Biological: IC14;Other: Placebo | Implicit Bioscience | NULL | Withdrawn | 18 Years | 70 Years | All | 0 | Phase 2 | United States |
| 2 | NCT04309604 (ClinicalTrials.gov) | October 18, 2019 | 12/3/2020 | IC14 for ALS Patients Expanded Access | IC14 for ALS Patients Expanded Access | Amyotrophic Lateral Sclerosis | Biological: IC14 | Implicit Bioscience | Massachusetts General Hospital | No longer available | 18 Years | N/A | All | United States | ||
| 3 | NCT03474263 (ClinicalTrials.gov) | September 1, 2019 | 9/3/2018 | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) | A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With | Amyotrophic Lateral Sclerosis | Biological: Biologic: IC14 (monoclonal antibody against human CD14) | Implicit Bioscience | NULL | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 2 | Australia;United States |
| 4 | NCT03508453 (ClinicalTrials.gov) | August 15, 2019 | 16/4/2018 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron Disease | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Biological: IC14;Other: Placebo | Implicit Bioscience | NULL | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | Australia |
| 5 | NCT03487263 (ClinicalTrials.gov) | October 1, 2017 | 9/3/2018 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | Motor Neuron Disease;Amyotrophic Lateral Sclerosis | Biological: IC14 | Implicit Bioscience | Royal Brisbane and Women's Hospital | Completed | 18 Years | 75 Years | All | 10 | Phase 1 | Australia |